Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Hickey
Anthony John Rodney Hickey, Auckland NZ
| Patent application number | Description | Published |
|---|---|---|
| 20100160428 | TREATMENT OF MITOCHONDRIA-RELATED DISEASES AND IMPROVEMENT OF AGE-RELATED METABOLIC DEFICITS - Treatment of mitochondrial related conditions in mammals with antagonists or chelating agents of copper (II), preferably tetramines or penicillamines. These agents affect TGF-beta, Smad 4, collagen IV, cytochrome C oxidase and erectile dysfunction. | 06-24-2010 |
Deidre Mary Bernadette Hickey, Harlow GB
| Patent application number | Description | Published |
|---|---|---|
| 20100144765 | 5,6-TRIMETHYLENEPYRIMIDIN-4-ONE COMPOUNDS - Pyrimidone compounds of formula (I): | 06-10-2010 |
Deirdre Mary Bernadette Hickey, Stevenage GB
| Patent application number | Description | Published |
|---|---|---|
| 20090186867 | Substituted Diketopiperazines As Oxytocin Antagonists - A method of treating or preventing diseases or conditions mediated through the action of oxytocin which comprises administering to a human in need thereof of an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. | 07-23-2009 |
| 20090247541 | Novel compounds - Compounds of formula (I) | 10-01-2009 |
| 20100305127 | NOVEL COMPOUNDS - Compounds of formula (I) | 12-02-2010 |
| 20110152262 | NOVEL COMPOUNDS - Compounds of formula (I) | 06-23-2011 |
Deirdre Mary Bernadette Hickey, Harlow GB
| Patent application number | Description | Published |
|---|---|---|
| 20090118313 | Novel Compounds - Pyrimidone compounds of formula (I): | 05-07-2009 |
| 20090170877 | 5,6-Trimethylenepyrimidin-4-one compounds - Pyrimidone compounds of formula (I): | 07-02-2009 |
Kenneth Hickey, Dublin IE
| Patent application number | Description | Published |
|---|---|---|
| 20080198202 | Microfluidic Architecture - A microfluidic architecture is disclosed. The microfluidic architecture includes a substrate having an edge and a thin film stack established on at least a portion of the substrate adjacent the edge. The thin film stack includes a non-conducting layer and a seed layer, where the seed layer is positioned such that a portion of the non-conducting layer is exposed. A chamber layer is established on at least a portion of the seed layer. The non-conducting layer, the seed layer, and the chamber layer define a microfluidic chamber. A layer having a predetermined surface property is electroplated on the chamber layer and on at least one of another portion of the seed layer and the exposed portion of the non-conducting layer. | 08-21-2008 |
Marianne Hickey, Bristol GB
| Patent application number | Description | Published |
|---|---|---|
| 20110276944 | NATURAL LANGUAGE TEXT INSTRUCTIONS - A computer displays a graphical user interface (GUI) that includes a control and receives text instructions in a natural language that describe a location of the control on the GUI. The text instructions instruct an application to perform a user interface (UI) event on the control. | 11-10-2011 |
Mark Brendan Hickey, Victoria AU
| Patent application number | Description | Published |
|---|---|---|
| 20090209738 | Method for separating keratinous proteins from materials - A process for separating keratinous proteins from a keratin-containing material, the process comprising the steps of: subjecting the keratin-containing material to reduction in a liquid medium to solubilise the keratinous proteins under conditions that minimise hydrolysis of the keratinous proteins, to yield a solution of keratinous proteins and undissolved solids; subjecting the solution of keratinous proteins to peroxide oxidation, without any intervening keratin precipitation step; and separating the solution of keratinous proteins from the undissolved solids prior to, at the same time as, or following the oxidation step. Preferred conditions for performing the reduction step involve contacting the keratin-containing material with a solution of an alkali metal sulfide reducing agent at a temperature of between 25 C and 50 C for a time of between 30 and 90 minutes, assuming atmospheric pressure. The peroxide oxidation is suitably carried out within not more than 4 hours after the reduction step, and involves reducing the pH of the solution to a level not less than pH 10, although pH 11.3 is most preferred. The product is demonstrated to have a principal fraction that has a molecular weight above 10 kDa, reflecting that the disulfide bonds in the keratinous proteins are broken without hydrolysis of the proteins. | 08-20-2009 |
Pascal Hickey, North Ryde AU
| Patent application number | Description | Published |
|---|---|---|
| 20090004282 | Method of Particle Formation - A method of co-formulating two or more pharmaceutically active compounds into a particulate product including contacting a dense, supercritical or near-critical fluid With a suspension of a first active compound in a medium that is miscible with the dense fluid and a solution of a second active compound in a solvent that is miscible with the dense fluid. The product may be the first active agent coated with the second active agent. The method may use coaxial nozzles for the fluid, media or solvents. The method may be applied to production of dry powders for inhalation including beta-agonists and corticosteroids. Apparatus for use in the method comprising means for streams of solvents, media and dense fluids to enter a precipitation chamber at substantially the same point and means for collection of particles under gravity in one or more collection chambers. | 01-01-2009 |